Breast Cancer — Expanded Access Programs

• Study Comparing 5-Day vs. 9-Day Whole Breast Radiation with Boost for Early-Stage Breast Cancer — University of Utah
• Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
• Study on the Safety and Effectiveness of ENV-501 for Patients with HER3-Positive Solid Tumors — Endeavor Biomedicines, Inc.
• Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
• Phase 2 Study of Zanidatamab and Chemotherapy for HER2-positive Breast Cancer Before Surgery — Jazz Pharmaceuticals
• Phase 2 Study of Zanidatamab for Early Stage HER2 Positive Breast Cancer — M.D. Anderson Cancer Center
• Phase 2 Study of PCS6422 with Capecitabine for Advanced or Metastatic Breast Cancer — Processa Pharmaceuticals
• Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
• Study on [177Lu]Lu-NeoB and Capecitabine for Treating Advanced Breast Cancer — Novartis Pharmaceuticals
• Study on AZD8205 Alone or with Other Cancer Drugs for Advanced or Metastatic Solid Tumors — AstraZeneca
• Phase II Study on Inavolisib, Ribociclib, and Fulvestrant for Advanced Breast Cancer — Hoffmann-La Roche
• Phase II Study of Sacituzumab Govitecan and Pembrolizumab Before Surgery for Early-stage Triple-negative Breast Cancer Resistant to Immunochemotherapy — M.D. Anderson Cancer Center
• Phase III Study on Dato-DXd and Durvalumab for Pre- and Post-Surgery Treatment of Certain Types of Breast Cancer — AstraZeneca
• Phase III Study of Dato-DXd With or Without Durvalumab vs. Chemotherapy and Pembrolizumab for PD-L1 Positive Advanced Triple-negative Breast Cancer — AstraZeneca
• Phase 3 Study Comparing Dato-DXd to Standard Chemotherapy in Patients with Advanced HR-Positive, HER2-Negative Breast Cancer — AstraZeneca
• Phase II Study of Hormone Therapy, Pertuzumab, and Trastuzumab for Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Hoffmann-La Roche
• Study on Inavolisib, Palbociclib, and Fulvestrant for Advanced Breast Cancer with PIK3CA Mutation — Hoffmann-La Roche
• Study on Inavolisib with CDK4/6 Inhibitor and Letrozole vs Placebo for Advanced Breast Cancer with Specific Mutations — Hoffmann-La Roche
• Study Comparing Inavolisib Plus Fulvestrant with Alpelisib Plus Fulvestrant for Advanced Breast Cancer with Specific Mutations — Hoffmann-La Roche
• Study on Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) for Older Adults with Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on Dato-DXd for Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer — AstraZeneca
• Study Comparing Dato-DXd with Chemotherapy for Patients with Advanced Triple-negative Breast Cancer Not Suitable for PD-1/PD-L1 Inhibitors — AstraZeneca
• Study on Dato-DXd With or Without Durvalumab Compared to Other Treatments for Stage I-III Triple-negative Breast Cancer After Initial Therapy (TROPION-Breast03) — AstraZeneca
• Study on Disitamab Vedotin for Adults with Advanced HER2 Positive Breast Cancer — Pfizer
• Study Comparing Elacestrant to Standard Hormone Therapy in Women and Men with Early Breast Cancer at High Risk of Returning — Stemline Therapeutics, Inc.
• Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
• Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
• Study on Nonsteroidal Aromatase Inhibitors and Abemaciclib for Postmenopausal Women with Breast Cancer — Eli Lilly and Company
• Study on Olaparib and Pembrolizumab for Treating Triple Negative or Hormone Receptor-Positive HER2-Negative Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
• Study on Radiation Therapy with Pembrolizumab and Olaparib for Women with Certain Types of Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on SDX-7320 and Eribulin Combination for Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on T-DXd for Patients with Advanced HER2 Positive Breast Cancer, With or Without Brain Metastasis — AstraZeneca
• Study on How Hormone Therapy Before Surgery Affects Breast Cancer Treatment Outcomes — Memorial Sloan Kettering Cancer Center
• Study Comparing Tobemstomig and Nab-Paclitaxel with Pembrolizumab and Nab-Paclitaxel for Untreated PD-L1-Positive Advanced Triple-Negative Breast Cancer — Hoffmann-La Roche
• Study on Adding Targeted Radiation Therapy to Standard Drug Treatment for Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on GDC-4198 Alone and with Giredestrant Compared to Abemaciclib and Giredestrant for Advanced ER+ HER2- Breast Cancer — Genentech, Inc.
• Study on the Safety and Effects of PF-07220060 and PF-07104091 in People with Breast Cancer and Other Solid Tumors — Pfizer
• Study on PF-07248144 and Fulvestrant for HR-positive, HER2-negative Advanced or Metastatic Breast Cancer After Previous Treatment — Pfizer
• Study on Vepdegestrant and PF-07220060 for Advanced or Metastatic Breast Cancer — Pfizer
• Study on Inavolisib Treatments for Early-Stage, PIK3CA-Mutated Breast Cancer — Hoffmann-La Roche
• Study on AMXI-5001 for Treating Advanced Cancers — AtlasMedx, Incorporated
• Study on Adjusting Abemaciclib Dose to Maintain Treatment Intensity for High-Risk Early-Stage HR+HER2- Breast Cancer — University of Illinois at Chicago
• Study on Abemaciclib and Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer — Icahn School of Medicine at Mount Sinai
• Study on Abemaciclib and Hydroxychloroquine for Targeting Minimal Residual Disease in Breast Cancer — Abramson Cancer Center at Penn Medicine
• Study on Abraxane® With or Without Mifepristone for Advanced Triple-Negative Breast Cancer — University of Chicago
• Accelerated Radiation Therapy for Breast Cancer and Nearby Lymph Nodes — Weill Medical College of Cornell University
• Study on Chemoradiation and Biomarkers for High-Risk Breast Cancer — University of Virginia
• Study on Endocrine Therapy or Targeted Radiation After Lumpectomy for Low-Risk Breast Cancer in Women Over 65 — UNC Lineberger Comprehensive Cancer Center
• Study on Using Genetically Modified White Blood Cells to Treat Cancers with CD70 Marker — National Cancer Institute (NCI)
• Study on Using Genetically Modified T-Cells to Target Cancer Mutations in People with Metastatic Cancer — National Cancer Institute (NCI)
• Study on Aggressive Local Therapy for Bone-Only Metastasis to Improve Outcomes in Breast Cancer Patients — M.D. Anderson Cancer Center
• Study on Anastrozole, Fulvestrant, and Abemaciclib for HR+HER2- Metastatic Breast Cancer — University of California, Irvine
• Study on Using Artificial Intelligence to Guide CDK4/6 Inhibitor Treatment in Advanced Breast Cancer — University of California, San Diego
• Study on Accelerated Super-Hypofractionated Breast Brachytherapy for Breast Cancer — Virginia Commonwealth University
• ATEMPT 2.0: Comparing Two Treatments After Surgery for HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• Study on Atezolizumab and Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA) — Dana-Farber Cancer Institute
• Study on Atezolizumab and Tivozanib for Treating Certain Hard-to-Treat Cancers — University of Florida
• ATOP Trial: Investigating T-DM1 for HER2 Positive Breast Cancer — Dana-Farber Cancer Institute
• Study on Avelumab or Hydroxychloroquine, With or Without Palbociclib, to Eliminate Dormant Breast Cancer — Abramson Cancer Center at Penn Medicine
• Study on Axelopran for Advanced Cancer in Patients Using Opioids — HealthPartners Institute
• Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
• Phase II Study of CMC Regimen for Early Stage Breast Cancer — University of Illinois at Chicago
• Study on Biomarker Optimization of Pre-Surgery Therapy in Breast Cancer — University of Illinois at Chicago
• Study on Preoperative Pembrolizumab and Radiation for Breast Cancer — Stephen Shiao
• BreastVAX: Enhancing Immunotherapy with Radiation Boost for Early Breast Cancer — Abramson Cancer Center at Penn Medicine
• Study on Carboplatin and Nab-Paclitaxel With or Without Vorinostat for Treating Women with Newly Diagnosed Operable Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on Ribociclib with Hormone Therapy for ER-positive Breast Cancer — Massachusetts General Hospital
• Study on CFI-402257, a New Drug for Solid Tumors and Breast Cancer with Fulvestrant — Treadwell Therapeutics, Inc
• Study on Cisplatin, Romidepsin, and Nivolumab for Locally Recurrent or Metastatic Triple Negative Breast Cancer — Priyanka Sharma
• Study on the Safety of Palbociclib with Hormone Therapy Before Surgery for Breast Cancer — University of Nebraska
• Study on Combination Chemotherapy With or Without Trastuzumab for Stage II or III Breast Cancer — City of Hope Medical Center
• Study on Combined Immunotherapies for Metastatic ER+ Breast Cancer — Weill Medical College of Cornell University
• Study Comparing Two Doses of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer — AstraZeneca
• Study on Shorter vs. Longer Proton Radiation Therapy for Breast Cancer — Proton Collaborative Group
• Study on Turning HR+ Breast Cancer into a Personalized Vaccine — Weill Medical College of Cornell University
• Study on How Tumor Shrinkage Before Surgery Relates to Remaining Cancer in Early Breast Cancer Patients — Baylor Breast Care Center
• Study on DATOpotamab Deruxtecan for Breast Cancer That Has Spread to the Brain — Sarah Sammons, MD
• Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• DNA-Guided Second Line Adjuvant Therapy for High Risk Stage II-III Hormone Receptor Positive, HER2 Negative Breast Cancer — Criterium, Inc.
• Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
• Study Comparing DS-8201a and T-DM1 for HER2-Positive Breast Cancer That Cannot Be Removed or Has Spread — Daiichi Sankyo
• Study on Durvalumab with Trastuzumab and Pertuzumab for HER2-Enriched Breast Cancer — The Methodist Hospital Research Institute
• Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
• Study on the Effectiveness and Safety of 500mg Fulvestrant for Breast Cancer — Beth Israel Deaconess Medical Center
• EMERALD: Study on Using Only Radiation Therapy After Surgery in ER+ Breast Cancer for Women Aged 60 and Older — M.D. Anderson Cancer Center
• Study on Endocrine Therapy With or Without Abemaciclib After Surgery for Breast Cancer — Eli Lilly and Company
• Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score — Washington University School of Medicine
• ERADICATE: Study of Elacestrant and Trastuzumab Deruxtecan for Advanced Breast Cancer Resistant to CDK4/6 Inhibitors and Hormone Therapy — Sarah Sammons, MD
• Study on Adding Chemotherapy to Hormone Therapy for Premenopausal Women with Early-Stage ER-Positive/HER2-Negative Breast Cancer — NRG Oncology
• Study on Talazoparib for Treating Metastatic Breast Cancer with BRCA Mutations — Massachusetts General Hospital
• Study on New Biomarker-Driven Treatments for Advanced Breast Cancer — UNC Lineberger Comprehensive Cancer Center
• Expanded Access for Treating Cancers with RET Activation — Eli Lilly and Company
• Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
• Study on Using Enzalutamide for Early Stage Androgen Receptor Positive Triple Negative Breast Cancer — Memorial Sloan Kettering Cancer Center
• First-in-Human Study of STX-478 Alone and with Other Cancer Treatments for Advanced Solid Tumors — Scorpion Therapeutics, Inc.
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Celcuity Inc
• Study on HER2 FPBMC Treatment for Patients with Metastatic Breast and Prostate Cancer — University of Virginia
• HERizon-Breast: Personalized Treatment Study for Long-Term Remission in HER2+ Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on Higher or Standard Daily Radiation Therapy for Early-Stage Breast Cancer After Surgery — Radiation Therapy Oncology Group
• I-SPY Trial: New and Personalized Treatments for Breast Cancer Before Surgery — QuantumLeap Healthcare Collaborative
• Study on Early Treatment and Surgery for Breast Cancer with Lymph Node Involvement — Alice Chung
• Study Comparing Two Types of Radiation Therapy for Early Stage Breast Cancer After Lumpectomy — Rocky Mountain Cancer Centers
• Study on Letrozole with Ribociclib or Placebo as Pre-Surgery Treatment for ER-positive, HER2-negative Early Breast Cancer — Qamar Khan
• Study on Using Circulating Tumor DNA to Predict Early Treatment Changes for Patients with Stage IV Breast Cancer — University of Miami
• Study on Using Genetically Modified T Cells to Treat Malignant Pleural Disease — Memorial Sloan Kettering Cancer Center
• Access Programs for Alpelisib (BYL719) — Novartis Pharmaceuticals
• Managed Access Programs for LEE011, Ribociclib — Novartis Pharmaceuticals
• Study on Margetuximab or Trastuzumab for Stage II-III HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• Study on Predicting Endocrine Resistance in Hormone Receptor-Positive HER2-Negative Breast Cancer — Medical College of Wisconsin
• Study on Using Carboplatin and Docetaxel Before Surgery for Triple Negative Breast Cancer — Mothaffar Rimawi
• Study on Neoadjuvant Endocrine Therapy, Palbociclib, and Avelumab for Estrogen Receptor Positive Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab for HER2-Positive Breast Cancer — University of Texas Southwestern Medical Center
• Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC — University of Kansas Medical Center
• NeoTAILOR: A Biomarker-Directed Approach to Guide Pre-Surgery Treatment for Stage II/III ER-Positive, HER2-Negative Breast Cancer — Washington University School of Medicine
• Study on Nivolumab and Ipilimumab for Treating Metastatic Hypermutated HER2-negative Breast Cancer — Dana-Farber Cancer Institute
• Study on Niraparib and Dostarlimab for BRCA Mutated Breast Cancer — Dana-Farber Cancer Institute
• Study on Nivolumab, Ipilimumab, and Bicalutamide for HER2 Negative Breast Cancer Patients — Providence Health & Services
• Study on Olaparib as Additional Treatment for Patients with High-Risk HER2 Negative Breast Cancer with BRCA Mutations — AstraZeneca

Looking for a program not shown above? Search the full catalog for “Breast Cancer” to see every match including additional filters.